Kallyope is a company.
Kallyope has raised $481.0M across 5 funding rounds.
Key people at Kallyope.
Kallyope has raised $481.0M in total across 5 funding rounds.
Kallyope has raised $481.0M in total across 5 funding rounds.
Kallyope's investors include Andreessen Horowitz, Contrarian Ventures, INKEF Capital, Lux Capital, Mosaic Ventures, PentaLab, The Column Group, Union Square Ventures, Wind Ventures, ARCH Venture Partners, Venrock.
Kallyope is a New York City-based biotechnology company founded in 2015 that develops therapeutics targeting the gut-brain axis to address metabolic, neurological, and gastrointestinal diseases.[1][2][3][6] It integrates technologies like single-cell genomics, neural circuit mapping, computational biology, sequencing, bioinformatics, and neural imaging to discover gut-restricted small molecules that modulate gut-brain signaling, serving patients with conditions such as obesity, type 2 diabetes, gastrointestinal barrier diseases, immunology, inflammation, and central nervous system disorders.[1][3][4][5] The company solves unmet needs in these areas by leveraging the gut as the body's largest accessible drug target for faster, more successful drug development with localized action, evidenced by strong growth including a $44M Series A in 2015 and a $236M Series D to advance over 20 pipeline programs and four clinical compounds.[3][4]
Kallyope was co-founded in 2015 by renowned scientists Charles Zuker, Ph.D. (serial entrepreneur, co-founder of Aurora Biosciences and Senomyx), Tom Maniatis, Ph.D. (Lasker Award winner, co-founder of Genetics Institute, New York Genome Center, ProScript, and Acceleron Pharma), and Richard Axel, M.D. (2004 Nobel Prize winner), with backing from Lux Capital.[2][3] The idea emerged from breakthroughs in gut-brain biology, enabled by recent advances in sequencing, genetics, circuit mapping, and imaging, which were not feasible just years prior.[3] Early traction came swiftly with a $44M Series A launch, led by inaugural CEO Nancy Thornberry (30+ years at Merck, leading diabetes and endocrinology), who assembled talent from Columbia, Google, and Bloomberg; by 2021, under President and CEO Jay Galeota, it raised $236M Series D after advancing programs in diabetes, obesity, and GI diseases.[3][4]
Kallyope rides the gut-brain axis trend, decoding how gut signals influence brain functions like appetite and metabolism amid rising obesity, diabetes, and neurodegeneration epidemics.[1][3][4][5] Timing aligns with post-2010s tech leaps in genomics and AI-driven biology, enabling what founders called impossible earlier, while market forces favor oral, localized therapies over systemic drugs for faster clinical paths and better tolerability.[3][4] It influences biotech by pioneering NYC as a hub (Alexandria Center HQ), attracting elite talent, and validating gut-restricted modalities—potentially reshaping pharma's approach to chronic diseases with >20 pipeline assets.[1][4][6]
Kallyope is primed to lead gut-brain therapeutics, with clinical readouts from lead programs in obesity/T2D and GI disorders likely driving partnerships or further funding in 2026+.[4] Trends like AI-accelerated discovery, precision gut microbiomics, and demand for non-invasive metabolic/CNS drugs will amplify its edge, potentially evolving it into a multi-billion platform via IPO or Big Pharma deals. As a founder-led innovator unlocking the gut's therapeutic vastness, Kallyope exemplifies biotech's shift toward biology's "final frontiers" for human health transformation.[2][4][5]
Key people at Kallyope.
Kallyope has raised $481.0M across 5 funding rounds. Most recently, it raised $240.0M Series D in February 2022.
